Midwest Biomedical Research, 211 East Lake St., Ste. 3, Addison, IL, 60101, USA.
Department of Applied Health Science, Indiana University School of Public Health, Bloomington, IN, USA.
Curr Atheroscler Rep. 2024 Nov 18;27(1):5. doi: 10.1007/s11883-024-01246-y.
Statins are first-line pharmacotherapy for the treatment of elevated low-density lipoprotein cholesterol and are generally well-tolerated. However, some patients may experience statin-associated muscle symptoms (SAMS). This paper reviews recommendations for identification and management of patients with SAMS.
The National Lipid Association and other professional societies have issued guidance to assist clinicians in identifying and managing patients with partial or complete statin intolerance. The most common reason for intolerance is SAMS. This review discusses strategies to achieve therapeutic objectives for atherogenic lipoprotein management in patients with SAMS. Many patients who experience SAMS can tolerate some degree of statin therapy and non-statin medications are available as adjunctive or alternative treatments. With a thorough clinician-patient discussion and shared decision-making, a treatment plan can be identified to achieve therapeutic objectives and reduce the risk of atherosclerotic cardiovascular disease.
他汀类药物是治疗升高的低密度脂蛋白胆固醇的一线药物治疗，通常具有良好的耐受性。然而，一些患者可能会出现他汀类药物相关的肌肉症状（SAMS）。本文综述了 SAMS 患者的识别和管理建议。
国家脂质协会和其他专业协会已发布指南，以协助临床医生识别和管理部分或完全不耐受他汀类药物的患者。不耐受的最常见原因是 SAMS。这篇综述讨论了在 SAMS 患者中实现致动脉粥样硬化脂蛋白管理治疗目标的策略。许多出现 SAMS 的患者可以耐受一定程度的他汀类药物治疗，并且还有非他汀类药物可用作辅助或替代治疗。通过彻底的医患讨论和共同决策，可以确定治疗计划以实现治疗目标并降低动脉粥样硬化性心血管疾病的风险。
